OPKO Health (OPK) Q1 2025 earnings summary

Executive summary

• Announced sale of BioReference Health's oncology and related clinical testing business to LabCorp for up to $225 million, with $192.5 million payable at closing and up to $32.5 million in earnouts; expected to close in H2 2025.

• BioReference Health will focus on urology diagnostics and core clinical testing, representing about $320 million in 2024 revenue.

• Advanced pharmaceutical pipeline, including GLP-1/glucagon analog (OPK-88006) for MASH and obesity, and MoDEx programs in phase I trials; collaboration with Entera Bio for oral GLP-1/glucagon tablet.

• Strategic restructuring and cost reductions in diagnostics, including a 7% workforce reduction and $19 million in annualized savings.

• Increased share repurchase authorization by $100 million, totaling $200 million; $40.2 million repurchased since July 2024.

Financial highlights

• Q1 2025 consolidated revenue: $149.95 million, down 14% year-over-year; net loss: $67.6 million ($0.10/share), improved from $81.8 million ($0.12/share) in Q1 2024.

• Diagnostic segment revenue: $102.8 million (including $25.1 million from assets being sold), down from $126.9 million in Q1 2024.

• Pharmaceutical segment revenue: $47.1 million, up slightly from $46.8 million in Q1 2024; product revenue down 8% to $34.8 million; IP/other revenue up 40% to $12.3 million due to BARDA contract growth.

• Operating loss for Q1 2025: $67.2 million (vs. $71.5 million in Q1 2024); diagnostics: $23.9 million (Q1 2025) vs. $34.4 million (Q1 2024); pharmaceuticals: $34.8 million (Q1 2025) vs. $27.7 million (Q1 2024).

• Ended Q1 2025 with $449.7 million in cash, cash equivalents, and restricted cash.

Outlook and guidance

• 2025 total revenue expected between $675 million and $685 million.

• Revenue from services: $405–$425 million; products: $165–$175 million; other revenue: $75–$85 million.

• BARDA revenue guidance revised to $38–$44 million; BARDA contract funding increased to $110 million, with $78 million remaining to be recognized through 2028.

• Costs and expenses expected between $825 million and $875 million, excluding $10–$14 million in non-recurring restructuring costs.

• Anticipated $100 million gain on LabCorp transaction upon closing.